IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors
Source: OncLive, November 2024
The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,
Treatment with the investigational preferentially expressed antigen in melanoma (PRAME)–targeted T-cell therapy IMA203 led to responses in patients with melanoma and other solid tumors, according to data from the phase 1 IMA203-101 trial (NCT03688124) presented at the 2024 SITC Annual Meeting.
IMA203 produced a confirmed overall response rate (ORR) of 54% and 60% among patients with cutaneous (n = 13) and uveal melanoma (n = 10), respectively. In each respective patient group, the unconfirmed ORR was 62% and 60%, tumor shrinkage occurred in 85% and 100%, and the disease control rate (DCR) at week 6 was 92% and 90%.